Protara Therapeutics Inc

TARA remains under Stage 4 decline pressure with a clear sequence of lower highs and lower lows, and price trading below the 9, 20, and 50 EMAs. Short-term pullback into the declining 9/20 EMA cluster presents an immediate sell opportunity. Key risks include a sustained reclaim of the 20 EMA accompanied by higher highs and lows, which would invalidate the bearish bias.

• ↑STARBORN-1 trial achieved 83% clinical success in initial cohort
• ↑All seven patients disease-free at 32 weeks post-treatment
• ↓BLA timeline hinges on trial completion; any delay hurts valuation